Literature DB >> 10798783

The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection.

A J Bathgate1, V Pravica, C Perrey, G Therapondos, J N Plevris, P C Hayes, I V Hutchinson.   

Abstract

BACKGROUND: The occurrence of acute rejection in orthotopic liver transplantation is unpredictable. The role of cytokines in the process of rejection is not entirely clear. We investigated polymorphisms in the genes encoding tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, and transforming growth factor (TGF)-beta1, which affect the amount of cytokine produced in vitro, in a liver transplant population to determine any association with acute rejection.
METHOD: DNA was extracted from whole blood of liver transplant patients. After amplification with polymerase chain reactions, the polymorphisms at TNF-alpha -308, IL-10 -1082, and TGF-beta1 +869 and +915 were determined using sequence-specific oligonucleotide probes. Acute cellular rejection was a clinical and histological diagnosis.
RESULTS: Acute cellular rejection requiring treatment occurred in 68 (48%) of 144 patients. Acute cellular rejection was significantly associated with the TNF-alpha -308 A/A genotype (P<0.02). There was no significant association with either IL-10 or TGF-beta1 polymorphisms in acute rejection.
CONCLUSION: Patients with a homozygous TNF-alpha -308 genotype A/A are more likely to suffer from acute cellular rejection after liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798783     DOI: 10.1097/00007890-200004150-00054

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.

Authors:  Faisal Khan; Swati Agrawal; Suraksha Agrawal
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Interleukin-10-1082G/A polymorphism and acute liver graft rejection: a meta-analysis.

Authors:  Fei Liu; Bo Li; Wen-Tao Wang; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen; Ming-Qing Xu; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  Integrating genomics into biobehavioral research: a transplantation exemplar.

Authors:  Carolyn J Driscoll; Debra Lyon; Nancy L McCain
Journal:  Biol Res Nurs       Date:  2010-12-30       Impact factor: 2.522

Review 4.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

Authors:  Bjarte Fosby; Tom H Karlsen; Espen Melum
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

5.  Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation: analysis of 155 donor-recipient pairs.

Authors:  Hideya Kamei; Satohiro Masuda; Taro Nakamura; Masatoshi Ishigami; Yasuhiro Fujimoto; Yasuhiro Ogura; Fumitaka Oike; Yasutsugu Takada; Nobuyuki Hamajima
Journal:  Hepatol Int       Date:  2013-07-31       Impact factor: 6.047

6.  Expression of CD80 on Kupffer cells is enhanced in cadaveric liver transplants.

Authors:  J Kwekkeboom; M A Kuijpers; B Bruyneel; S Mancham; E De Baar-Heesakkers; J N M Ijzermans; G J Bouma; P E Zondervan; H W Tilanus; H J Metselaar
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

7.  Lack of Association between Interleukin-10 Gene Polymorphisms and Graft Rejection Risk in Kidney Transplantation Recipients: A Meta-Analysis.

Authors:  Jiachuan Xiong; Yiqin Wang; Ying Zhang; Ling Nie; Daihong Wang; Yunjian Huang; Bing Feng; Jingbo Zhang; Jinghong Zhao
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

8.  HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation.

Authors:  Bjarte Fosby; Sigrid Næss; Johannes R Hov; James Traherne; Kirsten M Boberg; John Trowsdale; Aksel Foss; Pål-Dag Line; Andre Franke; Espen Melum; Helge Scott; Tom H Karlsen
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.